Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

BTG:LN

725.500 GBp 1.500 0.21%

As of 08:00:04 ET on 05/06/2015.

Snapshot for BTG PLC (BTG)

Open: 721.000 Day's Range: 718.000 - 728.500 Volume: 82,008
Previous Close: 724.000 52wk Range: 508.500 - 834.500 1-Yr Rtn: +31.67%

Stock Chart for BTG

No chart data available.
  • BTG:LN 725.500
  • 1D
  • 1M
  • 1Y
724.000
Interactive BTG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BTG

Current P/E Ratio (ttm) 65.8996
Estimated P/E(03/2015) 43.1250
Relative P/E vs. UKX 2.5211
Earnings Per Share (GBP) (ttm) 0.1099
Est. EPS (GBP) (03/2015) 0.1680
Est. PEG Ratio 1.7624
Market Cap (M GBP) 2,765.97
Shares Outstanding (M) 381.78
30 Day Average Volume 813,451
Price/Book (mrq) 4.5304
Price/Sale (ttm) 7.9738
Dividend Indicated Gross Yield -%
Cash Dividend (GBp) -
Dividend Ex-Date 06/07/2000
5 Year Dividend Growth -
Next Earnings Announcement 05/19/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BTG

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for BTG

BTG plc licenses, develops and commercializes pharmaceuticals and has a pipeline of development programs targeting neurological and other disorders, including varicose veins. The Company also has a substantial and growing revenue stream of milestone payments and royalties from out-licensed products.

Pamela Louise MakinCEO/Executive DirectorRolf SoderstromCFO/Executive Director
Peter StratfordCTO:Interventional MedicineGuenter R JanhoferChief Medical Officer/Head:Dev
More Company Profile & Key Executives for BTG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil